Rocket Pharmaceuticals Inc (NAS:RCKT)
$ 17.19 0.37 (2.2%) Market Cap: 1.56 Bil Enterprise Value: 1.28 Bil PE Ratio: 0 PB Ratio: 4.06 GF Score: 36/100

Rocket Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 06:30PM GMT
Release Date Price: $20.05 (-2.39%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

All right. Good afternoon, and welcome again to the 40th Annual JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst at the firm.

Our next presenting company this afternoon is Rocket Pharmaceuticals, and it's my pleasure to welcome Gaurav Shah, CEO, to talk to us a little bit about the company.

There is a Q&A session after the presentation. (Operator Instructions)

So with that, Gaurav, thanks for sharing some of your time with us today.

Gaurav D. Shah
Rocket Pharmaceuticals, Inc. - CEO & Director

Eric, happy New Year to you and to everybody, and thanks for joining us today. I'm going to call out the slide numbers as we go to keep it pretty simple.

So Slide 1 for now. Rocket is a clinical stage gene therapy company. Our vision is seeking gene therapy cures, very simple. The bottom line today is that we're very excited about this year for Rocket. We have multiple milestones, some readouts that could set us

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot